viking oral glp 1 to push GLP-1/GIP drug into phase III obesity trial Viking Therapeutics' weight-loss pill shows

Y1HGold proMrGST1 -pAbAi strain was tested on synthetic dextrose medium without uracil (SD/-Ura) agar plate to evaluate the background aureobasidin A resistance ( AbA r ) expression level

doi:10.1111/j.1432-1033.1992.tb16772.x

Animal studies (Neelakantan et al., Biochemical Pharmacology, 2018) showed significant body fat reduction without changes in food intake

Large studies have shown they also: Reduce the risk of heart attacks by about 20% Lower the chance of strokes Decrease heart failure hospitalizations Reduce overall cardiovascular death Some of these benefits happen independently of blood pressure changes, which means GLP-1 medications protect your heart through multiple pathways

PMID: 26175657